BICS: A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease

Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial (2024)
Journal Article
Devereux, G., Cotton, S., Nath, M., McMeekin, N., Campbell, K., Chaudhuri, R., Choudhury, G., De Soyza, A., Fielding, S., Gompertz, S., Haughney, J., Lee, A. J., MacLennan, G., Morice, A., Norrie, J., Price, D., Short, P., Vestbo, J., Walker, P., Wedzicha, J., …Lipworth, B. J. (2024). Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. Journal of the American Medical Association, https://doi.org/10.1001/jama.2024.8771

Importance: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that β-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial repor... Read More about Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.